KR101972073B1 - Composition for inhibition of aging comprising syringaresinol - Google Patents
Composition for inhibition of aging comprising syringaresinol Download PDFInfo
- Publication number
- KR101972073B1 KR101972073B1 KR1020180066106A KR20180066106A KR101972073B1 KR 101972073 B1 KR101972073 B1 KR 101972073B1 KR 1020180066106 A KR1020180066106 A KR 1020180066106A KR 20180066106 A KR20180066106 A KR 20180066106A KR 101972073 B1 KR101972073 B1 KR 101972073B1
- Authority
- KR
- South Korea
- Prior art keywords
- skin
- composition
- expression
- aging
- sirling
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- KOWMJRJXZMEZLD-UHFFFAOYSA-N syringaresinol Chemical compound COC1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(OC)C(O)=C(OC)C=3)CO2)=C1 KOWMJRJXZMEZLD-UHFFFAOYSA-N 0.000 title claims description 5
- LVUPFEOCDSHRBL-UHFFFAOYSA-N syringaresinol Natural products COc1cccc(OC)c1C2OCC3C2COC3c4c(OC)cccc4OC LVUPFEOCDSHRBL-UHFFFAOYSA-N 0.000 title claims description 5
- 230000032683 aging Effects 0.000 title abstract description 15
- 230000005764 inhibitory process Effects 0.000 title description 4
- 239000004480 active ingredient Substances 0.000 claims abstract description 16
- 241000208340 Araliaceae Species 0.000 claims description 17
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 17
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 17
- 235000008434 ginseng Nutrition 0.000 claims description 17
- 230000003020 moisturizing effect Effects 0.000 claims description 15
- 102000011990 Sirtuin Human genes 0.000 claims description 14
- 108050002485 Sirtuin Proteins 0.000 claims description 14
- 239000000284 extract Substances 0.000 claims description 11
- 230000008591 skin barrier function Effects 0.000 claims description 9
- 102000000344 Sirtuin 1 Human genes 0.000 claims description 7
- 108010041191 Sirtuin 1 Proteins 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000002537 cosmetic Substances 0.000 claims description 6
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 claims description 5
- 244000000231 Sesamum indicum Species 0.000 claims description 5
- 235000003434 Sesamum indicum Nutrition 0.000 claims description 5
- 235000004426 flaxseed Nutrition 0.000 claims description 5
- 235000013402 health food Nutrition 0.000 claims description 5
- 238000005728 strengthening Methods 0.000 claims description 4
- 239000004909 Moisturizer Substances 0.000 claims description 2
- 229930182494 ginsenoside Natural products 0.000 claims description 2
- 229940089161 ginsenoside Drugs 0.000 claims description 2
- 230000001333 moisturizer Effects 0.000 claims description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
- 235000011187 glycerol Nutrition 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 25
- 210000003491 skin Anatomy 0.000 description 56
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 230000000694 effects Effects 0.000 description 21
- 230000037303 wrinkles Effects 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 19
- 238000009472 formulation Methods 0.000 description 18
- 235000013399 edible fruits Nutrition 0.000 description 17
- 210000002510 keratinocyte Anatomy 0.000 description 15
- 230000009759 skin aging Effects 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 12
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 12
- 210000002950 fibroblast Anatomy 0.000 description 12
- 230000001737 promoting effect Effects 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 11
- 230000036560 skin regeneration Effects 0.000 description 11
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 10
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 10
- 230000011382 collagen catabolic process Effects 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 8
- 108010035532 Collagen Proteins 0.000 description 8
- 229920001436 collagen Polymers 0.000 description 8
- 102000007236 involucrin Human genes 0.000 description 8
- 108010033564 involucrin Proteins 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000037373 wrinkle formation Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 244000043261 Hevea brasiliensis Species 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 230000036572 transepidermal water loss Effects 0.000 description 5
- 229940058015 1,3-butylene glycol Drugs 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 4
- LTGPFZWZZNUIIK-LURJTMIESA-N Lysol Chemical compound NCCCC[C@H](N)CO LTGPFZWZZNUIIK-LURJTMIESA-N 0.000 description 4
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 4
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 description 4
- 210000002808 connective tissue Anatomy 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229940056692 resinol Drugs 0.000 description 3
- 230000037394 skin elasticity Effects 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102100028314 Filaggrin Human genes 0.000 description 2
- 101710088660 Filaggrin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- ACFGRWJEQJVZTM-LEJBHHMKSA-L Magnesium L-ascorbic acid-2-phosphate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1O ACFGRWJEQJVZTM-LEJBHHMKSA-L 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 235000002789 Panax ginseng Nutrition 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010063493 Premature ageing Diseases 0.000 description 2
- 208000032038 Premature aging Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- -1 lignan compound Chemical class 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000020712 soy bean extract Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- BWSWZBCSFZAYOB-CABCVRRESA-N (2s,4r)-1-dodecanoyl-4-hydroxypyrrolidine-2-carboxylic acid Chemical compound CCCCCCCCCCCC(=O)N1C[C@H](O)C[C@H]1C(O)=O BWSWZBCSFZAYOB-CABCVRRESA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 108700041153 Filaggrin Proteins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000003964 Histone deacetylase Human genes 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091080995 Mir-9/mir-79 microRNA precursor family Proteins 0.000 description 1
- 101000654471 Mus musculus NAD-dependent protein deacetylase sirtuin-1 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 241001600434 Plectroglyphidodon lacrymatus Species 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 241000219492 Quercus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003367 anti-collagen effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 108091047084 miR-9 stem-loop Proteins 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000011049 pearl Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000011546 protein dye Substances 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Cosmetics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 시링가레시놀을 유효 성분으로 포함하는 노화 억제용 조성물을 개시한다.The present invention discloses a composition for inhibiting aging comprising Sirling's recinol as an active ingredient.
Description
본 발명은 시링가레시놀을 포함하는 노화 억제용 조성물에 관한 것이다.The present invention relates to a composition for inhibiting aging comprising Sirling's lysinol.
피부는 빛에 직접적으로 노출되기 때문에 자외선에 가장 취약한 부분이다. 자외선에 노출된 피부는 그 정도에 따라 화상, 색소 침착, DNA 손상, 결합 조직의 변화, 암과 같은 생물학적 반응을 나타내게 된다. 또한 자외선에의 반복적인 노출은 피부의 조기 노화를 야기하게 되는데, 이러한 피부 노화는 주름 생성, 색소 침착, 결합 조직의 변이 및 표피 세포의 두께 변화 등으로 나타난다. Skin is the most vulnerable to ultraviolet light because it is directly exposed to light. Skin exposed to ultraviolet light will exhibit biological reactions such as burns, pigmentation, DNA damage, changes in connective tissue, and cancer, depending on its degree. Repeated exposure to ultraviolet light causes premature aging of the skin. Such skin aging is caused by wrinkle formation, pigmentation, changes in connective tissue, and changes in the thickness of epidermal cells.
피부의 결합 조직은 주로 콜라겐과 엘라스틴으로 이루어진다. 콜라겐과 엘라스틴은 피부에 탄력을 주므로 이들이 약해지면 피부가 쉽게 손상되고 노화된다. 상기 콜라겐의 분해에 관여하는 효소가 MMP(Matrix Metalloproteinase)이다. 피부 노화가 진행되면, MMP들의 발현이 증가되고, 증가된 MMP들이 피부의 콜라겐을 분해하게 된다. 이런 메커니즘이 반복되면 피부 주름이 생성되고 조기 노화가 진행된다.The connective tissue of the skin consists mainly of collagen and elastin. Collagen and elastin provide elasticity to the skin, making them easily damaged and aging as they weaken. The enzyme involved in the collagen degradation is MMP (Matrix Metalloproteinase). As skin aging progresses, the expression of MMPs increases, and increased MMPs break down collagen in the skin. Repeating this mechanism will cause skin wrinkles and premature aging.
TGF-β(transforming growth factor-β)는 여러 세포들의 성장과 분화에 관여하는 물질이다. 포유류에서 TGF-β는 3가지 다른 이성체(isoforms)로 존재하며, 그 중 TGF-β1은 진피층의 ECM(extracellular matrix) 형성에 가장 강한 활성을 나타내고, 조직의 복구와 분화에 관여한다. TGF-β1은 섬유아세포를 자극하여 Type I 및 Type Ⅲ 콜라겐, 피브로넥틴(fibronectin) 및 프로테오글리칸(proteoglycans) 등의 여러 ECM 성분들을 생산하게 한다. 따라서, TGF-β1의 생성을 촉진하는 물질은 섬유아세포의 성장을 촉진하고 피부 재생을 촉진함으로써 피부 노화를 방지하고 주름을 개선할 수 있을 것이다.TGF-β (transforming growth factor-β) is a substance involved in the growth and differentiation of various cells. In mammals, TGF-β is present in three different isoforms, of which TGF-β1 is the most active in the formation of extracellular matrix (ECM) in the dermis and is involved in tissue repair and differentiation. TGF-β1 stimulates fibroblasts to produce several ECM components, including Type I and Type III collagen, fibronectin, and proteoglycans. Therefore, a substance that promotes the production of TGF-? 1 can promote fibroblast growth and promote skin regeneration, thereby preventing skin aging and improving wrinkles.
피부 조직이 수분을 유지하기 위해서는, 피부 내 천연보습인자(Natural Moisturing Factor)가 증가하는 것이 필요하다. 천연보습인자의 주 성분인 아미노산은 표피 각질형성세포가 생산하는 필라그린(filaggrin)이라는 단백질의 분해에 의해 공급되기 때문에 필라그린의 생산이 촉진되면 보습 효과를 나타낼 수 있다. 또한 인보루크린(involucrin)은 피부 손실을 방지하는 세포 외피(cell envelope)의 형성 및 각질층의 구조화에 있어 매우 중요한 역할을 하는 인자이므로, 이의 발현이 촉진되면 역시 우수한 피부 보습 효과를 나타낼 수 있다.In order for the skin tissue to retain moisture, it is necessary to increase the natural moisturizing factor in the skin. Amino acid, which is the main component of natural moisturizing factor, is supplied by decomposition of filaggrin protein produced by epidermal keratinocyte. In addition, Involucrin plays a very important role in the formation of cell envelope and structuring of the stratum corneum to prevent skin loss. Therefore, it is possible to exhibit excellent skin moisturizing effect when its expression is promoted.
본 발명은 피부 주름 생성 억제, 피부 재생 능력 강화, 피부 보습 촉진 등을 통해 뛰어난 피부 노화 억제 효과를 가지는 조성물을 제공하고자 한다. 또한 본 발명은 주름 개선 또는 억제제, 피부 재생 촉진제 및 피부 보습제를 제공하고자 한다.The present invention provides a composition having excellent skin aging-inhibiting effect through inhibition of skin wrinkle formation, enhancement of skin regeneration ability, promotion of skin moisturizing, and the like. The present invention also provides a wrinkle improving or inhibiting agent, a skin regeneration promoting agent and a skin moisturizing agent.
본 발명의 일측면은 시링가레시놀(syringaresinol)을 유효 성분으로 포함하는 노화 억제용 조성물을 제공한다.One aspect of the present invention provides a composition for inhibiting aging comprising syringaresinol as an active ingredient.
본 발명의 다른 일측면은 시링가레시놀을 유효 성분으로 포함하는 조성물을 포함하는 주름 개선 또는 억제제, 피부 재생 촉진제 및 피부 보습제를 제공한다.Another aspect of the present invention provides a wrinkle improving or inhibiting agent, a skin regeneration promoting agent, and a skin moisturizing agent comprising a composition comprising Sirling's resinoid as an active ingredient.
본 발명에 따른 조성물은 시링가레시놀을 유효 성분으로 포함함으로써, SIRT 1의 발현을 증가시키고, 자외선으로 인한 MMP-9의 발현을 억제하며, 피부 탄력과 강도에 중요한 영향을 미치는 콜라겐의 분해를 억제함으로써, 피부 주름을 개선할 수 있다. 또한, 세포의 재생을 촉진하는 TGF-β1의 발현을 증가시키므로 피부 세포 재생 촉진 및 피부 탄력 증진 효과가 우수하다. 뿐만 아니라, 피부 보습 인자인 필라그린 및 인보루크린의 발현을 촉진함으로써, 뛰어난 피부 보습 효과를 나타낼 수 있다. 이와 같은 작용을 통해 시링가레시놀을 포함하는 조성물은 노화, 구체적으로 피부 노화, 더 구체적으로 자외선에 의한 피부 노화를 억제함에 있어 우수한 효과를 가질 수 있다.The composition according to the present invention increases the expression of
도 1은 인삼 열매 추출물로부터 시링가레시놀을 분리 및 정제하는 방법을 나타낸 개략도이다.
도 2는 시링가레시놀의 화학 구조이다.
도 3은 각질형성세포에서 시링가레시놀의 SIRT 1 발현 촉진 효과를 나타낸 그래프이다.
도 4는 섬유아세포에서 시링가레시놀의 SIRT 1 발현 촉진 효과를 나타낸 그래프이다.
도 5는 시링가레시놀의 필라그린과 인보루크린의 발현 촉진 효과를 나타낸 그래프이다.
도 6는 시링가레시놀의 MMP-9 발현 및 콜라겐 분해 억제 효과를 나타낸 도면이다.
도 7은 시링가레시놀을 도포하거나 경구 투여한 경우 피부 주름 억제 효과를 나타낸 그래프이다.
도 8은 시링가레시놀을 도포하거나 경구 투여한 경우 표피 수분 손실(TEWL) 억제 효과를 나타낸 그래프이다.BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a schematic view showing a method for separating and purifying Siringagrelin from a ginseng fruit extract. FIG.
Figure 2 is the chemical structure of Sirling's lycinol.
FIG. 3 is a graph showing the effect of stimulating
FIG. 4 is a graph showing the effect of stimulating
FIG. 5 is a graph showing the effect of promoting the expression of pillar green and involucrin in Sirin Galsinol.
FIG. 6 is a graph showing the effect of Sirlinggalcinol on MMP-9 expression and collagen degradation inhibition. FIG.
Fig. 7 is a graph showing the skin wrinkle inhibiting effect when Sirling is applied with or without oral administration of resorcinol.
Fig. 8 is a graph showing the effect of inhibiting skin moisture loss (TEWL) when Sirling is applied or administered orally.
본 명세서에서 "피부"라 함은, 동물의 체표를 덮는 조직을 의미하는 것으로서, 얼굴 또는 바디 등의 체표를 덮는 조직뿐만 아니라, 두피와 모발을 포함하는 최광의의 개념이다. 본 명세서에서 “추출물"은 추출 방법, 추출 용매, 추출된 성분 또는 추출물의 형태를 불문하고, 천연물의 성분을 뽑아냄으로써 얻어진 물질을 모두 포함하는 광범위한 개념이다.As used herein, the term " skin " refers to a tissue covering the body surface of an animal, and is a concept of the broadest notion including a scalp and hair as well as a tissue covering a body surface such as a face or a body. As used herein, the term " extract " is a broad concept that encompasses all of the substances obtained by extracting components of natural products, regardless of the type of extraction method, extraction solvent, extracted component or extract.
시르투인 1(Sirtuin 1, SIRT 1)은 효모의 잠재 정보 조절자 2(silencing information regulator 2, Sir2)의 포유 동물 호몰로그로서 NAD+ 의존적인 히스톤 탈아세틸화 효소이다. SIRT 1은 히스톤, 전사인자 등 다양한 단백질의 탈인산화를 조절함으로써, 노화, 스트레스 저항성 등에 관여한다고 알려져 있으며, 인간 진피 세포 및 각질형성세포에서 SIRT 1가 활성화되거나 과발현되는 경우, 자외선 조사에 의한 MMP-9의 발현을 억제하여 콜라겐 분해를 방지한다고 알려져 있다. 이러한 결과는 SIRT 1의 활성 또는 발현 조절제가 피부 노화를 억제 또는 예방할 수 있다는 것을 의미한다. 그러나, 아직까지 SIRT 1의 발현을 증가시키면서 안정성이 있다고 알려진 물질은 없다.Sirtuin 1 (SIRT 1) is a NAD + dependent histone deacetylase that is a mammalian homologue of yeast potential information modulator 2 (
본 발명의 일측면은 시링가레시놀(syringaresinol)을 유효 성분으로 포함하는 노화 억제용 조성물을 제공한다. 본 명세서에서 노화는 나이가 들면서 일어나는 생체의 쇠퇴적인 변화 현상을 의미하며, 생리 활성 저하, 체내 대사 저하, 피부 노화를 포함한다. 상기에서 피부 노화는 자외선에 의해 주름이 생성되고, 보습 인자가 감소하며, 재생 능력이 상실된 상태를 포함한다.One aspect of the present invention provides a composition for inhibiting aging comprising syringaresinol as an active ingredient. In the present specification, aging means a phenomenon of decline of a living body caused by age, and includes a decrease in physiological activity, a decrease in metabolism in the body, and skin aging. The skin aging includes a state in which wrinkles are generated by ultraviolet rays, a moisturizing factor is reduced, and a regenerating ability is lost.
시링가레시놀은 SIRT 1의 발현을 4배 이상 증가시킬 수 있을 뿐만 아니라, 피부 재생 능력 지표인 TGF-β1의 발현을 증가시켜 피부 재생을 촉진하고, 자외선으로 인한 MMP-9의 발현을 억제하여 자외선이 조사되지 않은 정도의 낮은 수준으로 MMP-9를 발현시킬 수 있다. 또한 시링가레시놀은 피부 탄력과 강도에 중요한 영향을 미치는 콜라겐의 분해, 구체적으로 자외선에 의한 콜라겐의 분해를 억제할 수 있다. 뿐만 아니라, 시링가레시놀은 피부 보습에 중요한 인자인 필라그린(filaggrin) 및 인보루크린(involucrin)의 발현을 촉진시켜 피부 건조를 방지하고 자외선에 의한 피부 장벽 손상을 방지하며, 손상된 피부 장벽을 빠르게 개선하여 피부 표피의 수분을 유지 시켜줄 수 있다. 그리고 시링가레시놀은 피부 결합 조직을 견고히 하여 피부 주름 생성을 억제하고 피부 탄력을 증진시킬 수 있다. 즉, 시링가레시놀을 유효 성분으로 포함하는 조성물은 주름 개선 또는 억제제, 피부 재생 촉진제 및 피부 보습제로 사용될 수 있다. 이와 같이 시링가레시놀은 피부 주름 생성 억제, 피부 재생 능력 강화, 피부 보습 촉진 작용을 하여 노화, 구체적으로 피부 노화, 더 구체적으로 자외선에 의한 피부 노화를 억제 또는 예방하는 효과가 뛰어나다. Sirling regicin not only increases the expression of
시링가레시놀은 도 2와 같은 화학 구조를 가지는 리그난계 화합물로, 화학 합성을 통해 얻거나, 아마씨, 황백, 오가피, 참깨 및 인삼 열매 중 하나 이상으로부터 추출할 수 있다. 상기 아마씨, 황백, 오가피 및 참깨는 각 식물의 잎, 줄기, 뿌리, 열매 또는 씨를 예로 들 수 있는 식물의 각 부위를 모두 포함하며, 인삼 열매는 인삼 열매 과피 또는 과육을 포함한다.Siringaricinol is a lignan compound having the chemical structure shown in Fig. 2, which can be obtained through chemical synthesis or can be extracted from one or more of flaxseed, white, ocher, sesame and ginseng. The flaxseed, yellowtail, oak, and sesame include all parts of the plant such as leaf, stem, root, fruit or seed of each plant, and the ginseng fruit includes ginseng fruit rind or flesh.
본 발명의 일측면에서, 시링가레시놀은 아마씨, 황백, 오가피, 참깨 및 인삼 열매 중 하나 이상을 물, 유기 용매 및 물과 유기 용매의 혼합물로 이루어진 군에서 선택된 하나 이상으로 추출하여 수득할 수 있다. 상기 유기 용매는 알코올, 아세톤, 에테르, 에틸아세테이트, 디에틸에테르, 에틸메틸케톤 및 클로로포름으로 이루어진 군에서 선택된 하나 이상을 포함하나, 이에 제한되는 것은 아니다. 상기 알코올은 C1~C5의 저급 알코올을 포함하며, C1~C5의 저급 알코올은 메탄올, 에탄올, 이소프로필알코올, n-프로필알코올, n-부탄올 및 이소부탄올로 구성된 군으로부터 선택되는 하나 이상을 포함하나, 이에 제한되는 것은 아니다.In one aspect of the present invention, Siringagresinol may be obtained by extracting at least one of flaxseed, yellow-white, ocher, sesame and ginseng fruits with at least one selected from the group consisting of water, organic solvent and mixture of water and organic solvent have. The organic solvent includes, but is not limited to, at least one selected from the group consisting of alcohol, acetone, ether, ethyl acetate, diethyl ether, ethyl methyl ketone and chloroform. Wherein the alcohol comprises a C 1 to C 5 lower alcohol and the C 1 to C 5 lower alcohol is selected from the group consisting of methanol, ethanol, isopropyl alcohol, n-propyl alcohol, n-butanol and isobutanol But is not limited thereto.
본 발명의 다른 일측면에서, 시링가레시놀은 아마씨, 황백, 오가피, 참깨 및 인삼 열매의 추출물로 조성물에 포함될 수 있으며, 그 중 노화 억제에 특히 효과적인 분획이 포함될 수 있다.In another aspect of the present invention, Sirling's lecithin may be contained in the composition as an extract of flaxseed, yellow-white, ocher, sesame and ginseng fruit, among which a fraction particularly effective for inhibiting aging may be included.
본 발명의 일측면에서, 시링가레시놀을 인삼 열매로부터 분리 및 정제하는 방법은 다음과 같은 단계를 포함할 수 있다. 인삼 열매 과육의 알코올 추출물을 제조하는 단계; 제조한 알코올 추출물을 물과 알코올 중 하나 이상을 포함하는 용매로 용출시켜 분획을 수득하는 단계; 및 수득한 분획에 대해 유기 용매를 전개 용매로 사용하여 크로마토그래피, 구체적으로 얇은 막 크로마토그래피(TLC)를 수행하는 단계. 상기에서 유기 용매는 알코올, 아세톤, 에테르, 에틸아세테이트, 디에틸에테르, 에틸메틸케톤 및 클로로포름으로 이루어진 군에서 선택된 하나 이상을 포함하며, 알코올은 C1~C5의 알코올을 포함한다. 본 발명의 일측면에 따른 조성물은 상기와 같이 정제된 시링가레시놀을 유효 성분으로 포함할 수 있다.In one aspect of the present invention, a method for separating and purifying Sirling's lycinol from ginseng fruit may comprise the following steps. Preparing an alcoholic extract of the ginseng fruit pulp; Eluting the alcohol extract with a solvent containing at least one of water and alcohol to obtain a fraction; And performing chromatography, specifically Thin Film Chromatography (TLC), on the obtained fractions using an organic solvent as a developing solvent. The organic solvent includes at least one selected from the group consisting of alcohol, acetone, ether, ethyl acetate, diethyl ether, ethyl methyl ketone and chloroform, and the alcohol includes C 1 to C 5 alcohols. The composition according to one aspect of the present invention may contain the purified syringes lecinol as an active ingredient as described above.
본 발명의 일측면에 따른 조성물은 조성물 전체 중량을 기초로 1 중량% 내지 80 중량%, 구체적으로 5 중량% 내지 60 중량%, 더 구체적으로 10 중량% 내지 30 중량%의 시링가레시놀을 포함할 수 있다. 상기 범위로 포함하는 경우 본 발명의 의도한 효과를 나타내기에 적절할 뿐만 아니라, 조성물의 안정성 및 안전성을 모두 만족할 수 있으며, 비용 대비 효과의 측면에서도 상기 범위로 사용하는 것이 적절할 수 있다. 구체적으로 시링가레시놀이 1 중량% 미만인 경우 충분한 노화 억제 효과를 얻을 수 없고, 80 중량%를 초과하는 경우 안전성 및 제형 안정성이 낮아질 수 있다.The composition according to one aspect of the present invention comprises from 1% to 80% by weight, in particular from 5% to 60% by weight, more specifically from 10% to 30% by weight, based on the total weight of the composition, can do. When it is included in the above range, it is not only suitable for exhibiting the intended effect of the present invention but also can satisfy both the stability and safety of the composition and may be suitably used within the above range in terms of cost effectiveness. Concretely, when the syringal ratio is less than 1% by weight, a sufficient aging inhibiting effect can not be obtained, and when it exceeds 80% by weight, safety and formulation stability may be lowered.
본 발명의 일측면은 시링가레시놀을 유효 성분으로 포함하는 피부 외용제용 조성물을 제공한다. 본 발명의 다른 일측면은 시링가레시놀을 유효 성분으로 포함하는 경구용 조성물을 제공한다. 시링가레시놀을 유효 성분으로 포함하는 조성물은 피부에 도포되거나, 경구 투여되는 경우 모두 우수한 노화 억제 효과를 나타낼 수 있다.One aspect of the present invention provides a composition for external application for skin comprising Sirling's recinol as an active ingredient. Another aspect of the present invention provides an oral composition comprising Sirling's lecithin as an active ingredient. The composition containing Sirling's recinol as an active ingredient can exert excellent aging-inhibiting effect when applied to the skin or orally administered.
본 발명의 일측면은 시링가레시놀을 유효 성분으로 포함하는 화장료 조성물을 제공한다. 상기 화장료 조성물은 노화 억제 효과를 나타낼 수 있으며, 구체적으로 피부 주름 생성 억제, 피부 재생 능력 강화, 피부 장벽 기능 강화, 피부 보습 촉진 등을 통해 피부 노화를 억제할 수 있다.One aspect of the present invention provides a cosmetic composition comprising Sirling's recinol as an active ingredient. The cosmetic composition of the present invention can exhibit an anti-aging effect, and specifically can inhibit skin aging by inhibiting skin wrinkle formation, enhancing skin regeneration ability, strengthening skin barrier function, and promoting skin moisturization.
본 발명에 따른 화장료 조성물은 국소 적용에 적합한 모든 제형으로 제공될 수 있다. 예를 들면, 용액, 수상에 유상을 분산시켜 얻은 에멀젼, 유상에 수상을 분산시켜 얻은 에멀젼, 현탁액, 고체, 겔, 분말, 페이스트, 포말(foam) 또는 에어로졸 조성물의 제형으로 제공될 수 있다. 이러한 제형의 조성물은 당해 분야의 통상적인 방법에 따라 제조될 수 있다.The cosmetic composition according to the present invention may be provided in all formulations suitable for topical application. For example, it may be provided as a solution, an emulsion obtained by dispersing an oil phase in an aqueous phase, an emulsion obtained by dispersing an oil phase in water, a suspension, a solid, a gel, a powder, a paste, a foam or an aerosol composition. Compositions of such formulations may be prepared according to conventional methods in the art.
본 발명에 따른 화장료 조성물은 보습제, 에몰리언트제, 계면 활성제, 자외선 흡수제, 방부제, 살균제, 산화 방지제, pH 조정제, 유기 및 무기 안료, 향료, 냉감제 또는 제한(制汗)제를 더 포함할 수 있다. 상기 성분의 배합량은 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 당업자가 용이하게 선정 가능하며, 그 배합량은 조성물 전체 중량을 기준으로 0.01 내지 5 중량%, 구체적으로 0.01 내지 3 중량%일 수 있다.The cosmetic composition according to the present invention may further comprise a moisturizing agent, an emollient agent, a surfactant, an ultraviolet absorber, an antiseptic, a bactericide, an antioxidant, a pH adjusting agent, organic and inorganic pigments, a fragrance, . The compounding amount of the above components can be easily selected by those skilled in the art within a range not to impair the objects and effects of the present invention. The amount thereof may be 0.01 to 5% by weight, specifically 0.01 to 3% by weight, have.
본 발명의 일측면은 시링가레시놀을 유효 성분으로 포함하는 약학 조성물을 제공한다. 상기 약학 조성물은 노화 억제 효과를 나타낼 수 있으며, 구체적으로 피부 주름을 피부 주름 생성 억제, 피부 재생 능력 강화, 피부 장벽 기능 강화, 피부 보습 촉진 등을 통해 피부 노화를 예방 또는 치료할 수 있다.One aspect of the present invention provides a pharmaceutical composition comprising Sirling's rescinol as an active ingredient. The pharmaceutical composition can exhibit an anti-aging effect. Specifically, skin wrinkles can be prevented or treated by inhibiting skin wrinkle formation, enhancing skin regeneration ability, strengthening skin barrier function, promoting skin moisturization, and the like.
본 발명의 일측면에 따른 약학 조성물은 경구, 직장, 국소, 경피, 정맥 내, 근육 내, 복강 내, 피하 등으로 투여될 수 있다.The pharmaceutical composition according to one aspect of the present invention may be administered orally, rectally, topically, transdermally, intravenously, intramuscularly, intraperitoneally, subcutaneously, and the like.
경구 투여를 위한 제형은 정제(錠劑), 환제(丸劑), 연질 및 경질 캅셀제, 과립제(顆粒劑), 산제, 세립제, 액제, 유탁제(乳濁濟) 또는 펠렛제일 수 있으나, 이에 제한되는 것은 아니다. 이들 제형은 유효 성분 이외에 희석제(예: 락토오스, 덱스트로오스, 수크로오스, 만니톨, 솔비톨, 셀룰로오스 또는 글리신), 활택제(예: 실리카, 탈크, 스테아르산 또는 폴리에틸렌 글리콜), 또는 결합제(예: 마그네슘 알루미늄 실리케이트, 전분 페이스트, 젤라틴, 트라가칸스, 메틸셀룰로오스, 나트륨 카르복시메틸셀룰로오스 또는 폴리비닐피롤리딘)를 함유할 수 있다. 경우에 따라 붕해제, 흡수제, 착색제, 향미제, 또는 감미제 등의 약제학적 첨가제를 함유할 수 있다. 상기 정제는 통상적인 혼합, 과립화 또는 코팅 방법에 의해 제조될 수 있다.Formulations for oral administration may be in the form of tablets, pills, soft and hard capsules, granules, powders, granules, solutions, emulsions or pellets, It is not. These formulations may contain, in addition to the active ingredient, a diluent such as lactose, dextrose, sucrose, mannitol, sorbitol, cellulose or glycine, a lubricant such as silica, talc, stearic acid or polyethylene glycol, or a binder such as magnesium aluminum Silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose or polyvinylpyrrolidine). And may optionally contain pharmaceutical additives such as disintegrants, absorbents, colorants, flavors, or sweeteners. The tablets may be prepared by conventional mixing, granulating or coating methods.
비경구 투여를 위한 제제는 주사제, 점적제, 로션, 연고, 겔, 크림, 현탁제, 유제, 좌제(坐劑), 패취 또는 분무제일 수 있으나, 이에 제한되는 것은 아니다.Formulations for parenteral administration may be, but are not limited to, injections, drops, lozenges, ointments, gels, creams, suspensions, emulsions, suppositories, patches or spraying agents.
본 발명의 일측면에 따른 약학 조성물의 유효 성분은 투여 받을 대상의 연령, 성별, 체중, 병리 상태 및 그 심각도, 투여 경로 또는 처방자의 판단에 따라 달라질 것이다. 이러한 인자에 기초한 적용량 결정은 당업자의 수준 내에 있으며, 이의 1일 투여 용량은 예를 들어 0.1mg/kg/일 내지 100mg/kg/일, 보다 구체적으로는 5 mg/kg/일 내지 50 mg/kg/일이 될 수 있으나, 이에 제한되는 것은 아니다. The effective ingredients of the pharmaceutical composition according to one aspect of the present invention will vary depending on the age, sex, weight, pathological condition and severity of the subject to be administered, route of administration, or judgment of the prescriber. Determination of the amount of application based on these factors is within the level of ordinary skill in the art and its daily dose is, for example, from 0.1 mg / kg / day to 100 mg / kg / day, more specifically from 5 mg / kg / day to 50 mg / / Day, but is not limited thereto.
본 발명의 일측면은 시링가레시놀을 유효 성분으로 포함하는 노화 억제용 식품 조성물을 제공한다. 상기 식품 조성물은 기호 식품 또는 건강 식품 조성물을 포함한다.One aspect of the present invention provides a food composition for inhibiting aging comprising Sirling's recinol as an active ingredient. The food composition comprises a preference food or a health food composition.
상기 식품 조성물의 제형은 특별히 한정되지 않으나, 예를 들어, 정제, 과립제, 분말제, 드링크제와 같은 액제, 캐러멜, 겔, 바 등으로 제형화될 수 있다. 각 제형의 식품 조성물은 유효 성분 이외에 해당 분야에서 통상적으로 사용되는 성분들을 제형 또는 사용 목적에 따라 당업자가 어려움 없이 적의 선정하여 배합할 수 있으며, 다른 원료와 동시에 적용할 경우 상승 효과가 일어날 수 있다.The formulation of the food composition is not particularly limited, but may be formulated into, for example, tablets, granules, powders, liquid preparations such as drinks, caramels, gels, bars and the like. The food composition of each formulation can be blended with the ingredients commonly used in the field in addition to the active ingredient without difficulty by those skilled in the art depending on the purpose of formulation or use, and synergistic effect can be obtained when the composition is applied simultaneously with other ingredients.
상기 유효 성분의 투여량 결정은 당업자의 수준 내에 있으며, 이의 1일 투여 용량은 예를 들어 0.1mg/kg/일 내지 5000mg/kg/일, 보다 구체적으로는 50 mg/kg/일 내지 500 mg/kg/일이 될 수 있으나, 이에 제한되지 않으며, 투여하고자 하는 대상의 연령, 건강 상태, 합병증 등 다양한 요인에 따라 달라질 수 있다.The dosage of the active ingredient is within the level of those skilled in the art and its daily dose is, for example, from 0.1 mg / kg / day to 5000 mg / kg / day, more specifically from 50 mg / kg / day, but it is not limited thereto, and may be varied depending on various factors such as the age, health condition, and complication of the subject to be administered.
이하, 실시예 및 실험예를 들어 본 발명의 구성 및 효과를 보다 구체적으로 설명한다. 그러나, 이들 실시예 및 실험예는 본 발명에 대한 이해를 돕기 위해 예시의 목적으로만 제공된 것일 뿐 본 발명의 범주 및 범위가 그에 의해 제한되는 것은 아니다.Hereinafter, the constitution and effects of the present invention will be described in more detail with reference to Examples and Experimental Examples. However, these examples and experimental examples are provided for illustrative purposes only in order to facilitate understanding of the present invention, and the scope and scope of the present invention are not limited thereto.
[실시예] 시링가레시놀의 분리 및 분석EXAMPLES Isolation and Analysis of Syringal Resinol
1. 인삼 열매의 전처리1. Pretreatment of ginseng fruit
생(生) 인삼 열매를 수확하고, 종자를 분리하여 제거한 후, 인삼 열매의 과피를 제거하고 과육만을 일광 건조 또는 열풍 건조 하여 인삼 열매 과육 건조물을 제조하였다.The raw ginseng fruit was harvested and the seeds were separated and removed. Then, the ginseng fruit was removed, and only the flesh was dried with sunlight or hot air to produce dried ginseng fruit pulp.
2. 인삼 열매 과육 추출물로부터 시링가레시놀의 분리 및 분석2. Isolation and Analysis of Syringal Resinol from Extracts of Fruits and Ginseng Fruits
상기에서 제조한 인삼 열매 과육 건조물 1kg에 물 또는 주정 3L를 가하여 상온 또는 환류 추출하고 여과한 다음 40~45℃에서 감압 농축하여 인삼 열매 과육 추출물 300g을 얻었다. 추출물에 에테르(ether)를 처리하여 지용성 성분을 제거한 후, 부탄올(butanol)로 조사포닌을 추출 및 농축하였다. 이를 분리, 정제하여 시링가레시놀을 얻었으며, 구체적인 방법은 다음과 같다. 먼저 시료 194 g을 역상 컬럼 크로마토그래피(reversed-phase(ODS) column chromatography)로 정제하였으며, 이때 용출 용매로 처음에는 100% 물을 사용하였고 메탄올을 10%씩 점차 증가시켜 최종적으로는 100% 메탄올 용매를 사용하였다. 그 결과 GB-1 내지 GB-10 분획물을 얻었으며, 이들 분획물 중 인간의 장수 유전자라고 불리는 SIRT 1 발현 활성을 나타낸 분획 GB-3을 선별하여 농축한 후 50% 수용성 메탄올(aqueous methanol)을 이용하여 세파덱스 LH-20 컬럼 크로마토그래피(Sephadex LH-20 column chromatography)를 수행하였다. 얻은 분획물 중 SIRT 1 발현 활성을 나타낸 GB-3-6(3F)을 선별하여 농축한 후, 클로로포름:메탄올(10:1)을 전개 용매로 예비 실리카겔(preparative silica gel) TLC를 수행하였고, 그 결과 Rf값 0.67의 활성 분획을 정제하였다. 상기 분리 및 정제 방법을 도식화하여 도 1에 나타내었다.To 1 kg of dried ginseng fruit powder prepared above, 3 liters of water or alcohol was added, and the mixture was extracted at room temperature or reflux, filtered and concentrated under reduced pressure at 40 to 45 ° C to obtain 300 g of ginseng fruit pulp extract. The extract was treated with ether to remove lipid soluble components, crude saponin was extracted with butanol and concentrated. This was separated and purified to obtain syringal lysinol. Specific methods are as follows. First, 194 g of the sample was purified by reversed-phase (ODS) column chromatography. At this time, 100% water was used as the elution solvent, and methanol was gradually increased by 10% Were used. As a result, the GB-1 to GB-10 fractions were obtained. The fraction GB-3 showing the SIRT1 expression activity, which is called the human longevity gene, was selected and concentrated. The fractions were concentrated using 50% aqueous methanol Sephadex LH-20 column chromatography was carried out using Sephadex LH-20 column chromatography. GB-3-6 (3F) showing the SIRT1 expression activity was selected and concentrated. TLC of preparative silica gel was performed using chloroform: methanol (10: 1) as a developing solvent. The active fraction having an Rf value of 0.67 was purified. The separation and purification method is schematically shown in FIG.
NMR 분광 분석과 데이터베이스 검색을 수행하여 분리 및 정제한 활성 화합물을 시링가레시놀(syringaresinol)로 동정할 수 있었다. 이를 재확인하기 위하여 질량(mass) 분석을 수행하였으며, ESI-mass를 positive mode에서 측정한 결과 [M+Na]+가 m/z 440.9에서, [2M+Na]+가 m/z 858.9에서 관찰되어 분자량이 418임을 알 수 있었다. 또한 NMR 분광 분석을 수행하여 화학 구조를 결정하였으며, 그 결과는 도 2와 같다. 도 2에서 볼 수 있듯이, 분리 및 정제한 활성 화합물은 시링가레시놀의 화학 구조를 가지고 있다.NMR spectroscopic analysis and database search were performed to identify the active compound isolated and purified as syringaresinol. Mass spectrometry was performed to confirm this. ESI-mass was measured in positive mode, and [M + Na] + was observed at m / z 440.9 and [2M + Na] + at m / z 858.9 The molecular weight was found to be 418. NMR spectroscopy was also performed to determine the chemical structure, and the results are shown in FIG. As can be seen in Fig. 2, the active compound isolated and purified has the chemical structure of siringa regicinol.
이와 같이 인삼 열매 과육으로부터 시링가레시놀을 분리하였다.In this way, singlingcecinol was isolated from the ginseng fruit pulp.
[실험예 1] 인간 각질형성세포와 섬유아세포에서 SIRT 1 발현 촉진 효과 평가[Experimental Example 1] Evaluation of promoting effect of SIRT1 expression on human keratinocytes and fibroblasts
인간 각질형성세포 및 섬유아세포에서 시링가레시놀의 SIRT 1 유전자 발현 촉진 효과를 평가하기 위하여 아래와 같은 실험을 수행하였다.The following experiments were performed to evaluate the effect of Sirling's resinoin on the expression of
1. 세포주와 세포 배양1. Cell line and cell culture
인간 각질형성세포주(human keratinocyte)인 HaCaT 혹은 인간 섬유아세포주(human fibroblast)인 HDF를 10% 우태아 혈청(fetal bovin serum)을 포함한 DMEM 배지(Dulbecco’s modified Eagle’s Medium, Gibco 1210-0038)에서 37℃, 5% CO2 조건 하 배양하였다.HaCaT, a human keratinocyte or HDF, a human fibroblast, was cultured in DMEM medium (Dulbecco's modified Eagle's Medium, Gibco 1210-0038) containing 10% fetal bovine serum at 37 ° C , 5% CO 2 .
2. SIRT 1 발현 증가 효과 평가2. Evaluation of SIRT1 expression increasing effect
상기에서 배양한 세포에 시링가레시놀을 DMSO에 녹여 20, 50, 100 μM 농도로 24시간 처리하였다. 별도로 배지 부피 1/1000의 DMSO를 처리한 세포를 음성 대조군으로 하였다. 각 시료를 처리한 세포들을 차가운 PBS로 2회 세척한 후 트리졸 시약(TRIzol agent, Invitrogen)으로 RNA를 추출하였다. 상기에서 추출하여 정량한 1 ㎍/㎕의 RNA와 역전사 시스템(Promega)을 이용하여 cDNA를 합성하였다. 합성한 cDNA 및 SIRT 1과 GAPDH의 각 유전자에 대해 미리 디자인된 프라이머(Primer)와 프루브(probe)(Applied biosystems; SIRT 1, Hs01009006_m1; GAPDH, Hs99999905_m1)를 이용하여 각 유전자들의 발현 양상을 측정하였다. PCR 반응과 분석은 로터-진 3000 시스템(Rotor-Gene 3000 system; Corbett Research, Sydney, Australia)을 이용하였다. 결과를 도 3(각질형성세포) 및 도 4(섬유아세포)에 나타내었다. The cells cultured in the above were dissolved in DMSO and treated at 20, 50 and 100 μM for 24 hours. Separately, cells treated with DMSO of 1/1000 volume of medium were used as a negative control. Cells treated with each sample were washed twice with cold PBS and RNA was extracted with TRIzol agent (Invitrogen). CDNA was synthesized using 1 ㎍ / 의 of RNA extracted and quantified as above and a reverse transcription system (Promega). Expression patterns of each gene were measured using primers and probes (Applied biosystems;
도 3 및 도 4에서 볼 수 있듯이, 시링가레시놀은 농도 의존적으로 인간 각질형성세포와 섬유아세포에서 SIRT 1의 발현을 4배 이상 증가시킬 수 있다.As can be seen in FIGS. 3 and 4, Sirling's rescinol can increase the expression of
[실험예 2] 인간 각질형성세포에서 필라그린과 인보루크린의 발현 촉진 효과 평가[Experimental Example 2] Evaluation of promoting effect of pilar green and involucrin in human keratinocytes
인간 각질형성세포에서 시링가레시놀의 필라그린(filaggrin)과 인보루크린 발현 촉진 효과를 평가하기 위하여 아래와 같은 실험을 수행하였다.The following experiments were carried out to evaluate the promoting effect of filaggrin and involucrin expression of siringagrelin in human keratinocytes.
1. 세포주와 세포 배양1. Cell line and cell culture
인간 각질형성세포주(human keratinocyte)인 HaCaT세포를 실험예 1과 실질적으로 동일한 방법으로 배양하였다.HaCaT cells, which are human keratinocytes, were cultured in substantially the same manner as in Experimental Example 1.
2. 필라그린과 인보루크린의 발현 증진 효과 평가2. Evaluation of the enhancement of expression of pilar green and invlorucrin
실험예 1과 실질적으로 동일한 방법으로 cDNA를 합성하고, 합성한 cDNA 및 필라그린, 인보루크린과 GAPDH의 각 유전자에 대해 미리 디자인된 프라이머(Primer)와 프루브(probe)(Applied biosystems; SIRT 1, Hs01009006_m1; GAPDH, Hs99999905_m1)를 이용하여 각 유전자들의 발현 양상을 실험예 1과 실질적으로 동일한 방법으로 측정하였다. 그 결과를 도 5에 나타내었다. CDNA was synthesized in substantially the same manner as in Experimental Example 1, and primers and probes (Applied biosystems;
도 5에서 볼 수 있듯이, 시링가레시놀은 농도 의존적으로 인간 각질형성세포에서 필라그린과 인보루크린의 발현을 증가시켰다. 이를 토대로 시링가레시놀은 피부 장벽 기능을 강화하고 피부 보습 효과를 가짐을 알 수 있다.As can be seen from Fig. 5, Siringagrelin increased the expression of pilar green and Involucrin in human keratinocytes in a concentration-dependent manner. Based on this, it can be seen that Sirling Gelsinol enhances the skin barrier function and has skin moisturizing effect.
[실험예 3] 인간 각질형성세포에서 MMP-9의 발현 및 콜라겐 분해 억제 효과 평가[Experimental Example 3] Evaluation of MMP-9 expression and collagen degradation inhibitory effect in human keratinocytes
인간 각질형성세포에서 시링가레시놀의 MMP-9의 발현 및 콜라겐 분해 억제 효과를 평가하기 위해 아래와 같은 실험을 수행하였다.The following experiments were conducted to evaluate the effect of inhibiting collagen degradation and expression of MMP-9 of siringagrelin in human keratinocytes.
1. 세포주와 세포 배양1. Cell line and cell culture
인간 각질형성 세포주(human keratinocyte)인 HaCaT세포를 실험예 1과 실질적으로 동일한 방법으로 배양하였다.HaCaT cells, which are human keratinocytes, were cultured in substantially the same manner as in Experimental Example 1.
2. 자외선 조사에 의해 증가된 MMP-9 발현 및 콜라겐 분해의 억제 효과 평가2. Evaluation of inhibitory effect of MMP-9 expression and collagen degradation increased by ultraviolet irradiation
상기 배양한 세포주를 트립신 처리하여 단일 세포 현탁액을 만들고 6-웰에 2 x 105 개씩 분주하여, 24 시간 배양하였다. 그 후 우태아 혈청이 포함되지 않은 DMEM 배지로 교환하여 다시 24시간 동안 배양한 후, DMSO에 녹인 50 μM 농도의 시링가레시놀을 처리하였다. 24시간 동안 처리한 다음, 인산 완충 용액(PBS)으로 세척하고, 인산 완충 용액을 넣은 상태에서 30 mJ/cm2 농도의 UVB를 조사하였다. 인산 완충 용액을 버리고, 다시 같은 농도의 시링가레시놀이 포함된 배지로 교환하였다. 대조군으로 시링가레시놀을 처리하지 않은 세포를 동일한 방법으로 배양하였다. 자외선 조사 24 시간 후, 시링가레시놀을 처리한 세포와 처리하지 않은 세포를 인산완충용액(PBS)으로 세척하고, 트립신을 처리하여 세포를 수거하고, 이에 8 M 우레아, 2% CHAPS, 50 mM DTT, 2 M 티오우레아(thiourea), 2 mM PMSF, 100 mg/ml 류펩틴(leupeptine)의 단백질 추출 완충 용액 500 ml을 처리한 후 10 분간 상온에서 방치하였다. 그 후 4℃에서 10 분간 15,000 g의 중력 가속도로 원심 분리하고, 상층액을 수거한 후 BIO-라드 단백질 염색제™(BIO-Rad Protein Dye Reagent™)을 이용하여 단백질을 정량하였다. 20 mg의 단백질을 8 % SDS-PAGE를 이용하여 크기 별로 분리하고, 50 V로 12 시간 동안 PDF(BioRad) 막에 블로팅(blotting)하였다. 이 블랏을 5% 무지방 우유 용액으로 1 시간 동안 블로킹 한 후 일차 항체로는 단일 항체 항-MMP-9(Santa Cruz, CA, USA)와 단일 항체 항-콜라겐 IV(Abcam, Cambridge, MA, USA)를, 이차 항체로는 호오스 래디쉬 퍼옥시다아제(horse radish peroxidase)가 결합된 항-마우스 IgG(amersham)를 이용하였고, Amersham 사의 enhanced chemiluminescence(ECL) 키트를 이용하여 반응시켰다. 반응시킨 블랏은 X선 후지 필름에 감광시킨 후 현상하여 단백질 발현 정도를 확인하였다. 필름 상의 밴드는 파워룩(PowerLook) 2100 XL(umax)를 이용하여 스캐닝한 후 이미지마스터 2D 엘리트(Amersham Bioscience) 이미지 분석 프로그램을 이용하여 분석하고, 그 결과를 도 6에 나타내었다.The cultured cell line was trypsinized to prepare a single cell suspension, which was then divided into 6 × 10 5 wells and cultured for 24 hours. After that, the cells were exchanged with DMEM medium not containing fetal bovine serum, cultured for another 24 hours, and treated with 50 μM seringagressin dissolved in DMSO. After treatment for 24 hours, the cells were washed with phosphate buffered saline (PBS) and irradiated with UVB at a concentration of 30 mJ / cm 2 in the presence of phosphate buffer solution. The phosphate buffer solution was discarded and replaced with a medium containing the same concentration of syringal lysinol. As a control, cells not treated with syringal lysinol were cultured in the same manner. Twenty-four hours after the ultraviolet irradiation, the cells treated with siringagrelin and the untreated cells were washed with phosphate buffered saline (PBS), treated with trypsin, and the cells were collected and washed with 8 M urea, 2% CHAPS, 50 mM 500 ml of protein extraction buffer solution of DTT, 2 M thiourea, 2 mM PMSF and 100 mg / ml leupeptine was treated and allowed to stand at room temperature for 10 minutes. After centrifugation at 15,000 g of gravity acceleration at 4 ° C for 10 minutes, the supernatant was collected and the protein was quantified using BIO-Rad Protein Dye Reagent ™. 20 mg of protein was separated by size using 8% SDS-PAGE and blotted onto a PDF (BioRad) membrane at 50 V for 12 hours. The blots were blocked with 5% non-fat milk solution for 1 hour. Single antibody anti-MMP-9 (Santa Cruz, CA, USA) and single antibody anti-collagen IV (Abcam, Cambridge, Mouse IgG (amersham) conjugated with horseradish peroxidase was used as a secondary antibody, and the reaction was carried out using an enhanced chemiluminescence (ECL) kit from Amersham. The reacted blot was sensitized to X-ray fuji film and developed to confirm the degree of protein expression. The bands on the film were scanned using a PowerLook 2100 XL (umax) and analyzed using an image master 2D Elite (Amersham Bioscience) image analysis program, the results of which are shown in FIG.
도 6에서 볼 수 있듯이, 자외선 조사에 의해 각질형성세포의 MMP-9 발현이 증가하고, 또한 콜라겐 분해가 촉진되어 콜라겐의 양이 감소한다. 그러나, 시링가레시놀을 처리하는 경우 자외선 조사에 의한 MMP-9 발현의 증가가 억제되어 콜라겐 분해를 방지되므로, 자외선에 의한 콜라겐 생성 감소를 막을 수 있다. 즉, 시링가레시놀은 MMP-9의 발현을 억제하고, 나아가 콜라겐의 분해를 억제하여 피부 주름을 예방 및 개선하고 나아가 피부 노화를 억제할 수 있음을 확인할 수 있다.As shown in FIG. 6, the ultraviolet irradiation increases the expression of MMP-9 in keratinocytes and promotes collagen degradation, thereby reducing the amount of collagen. However, in the case of treatment with Sirling's lycinol, increase of MMP-9 expression due to ultraviolet irradiation is suppressed and collagen degradation is prevented, so that reduction of collagen production due to ultraviolet rays can be prevented. That is, it can be confirmed that Sirling's recinol inhibits the expression of MMP-9, further inhibits collagen degradation, thereby preventing and improving wrinkles of the skin and further inhibiting skin aging.
[실험예 4] 섬유아세포에서 TGF-β1 발현 촉진 효과 평가[Experimental Example 4] Evaluation of promoting effect of TGF-beta1 expression in fibroblasts
섬유아세포에서 시링가레시놀의 TGF-β1 발현 촉진 효과를 평가하기 위해 아래와 같은 실험을 수행하였다.The following experiment was conducted to evaluate the effect of stimulating TGF-β1 expression of siringagrelin in fibroblasts.
1. 세포주와 세포 배양1. Cell line and cell culture
인간 섬유아세포주(human fibroblast)인 HDF를 실험예 1과 실질적으로 동일한 방법으로 배양하였다.HDF, a human fibroblast, was cultured in substantially the same manner as in Experimental Example 1.
2. TGF-β1 발현 증가 효과 평가2. Evaluation of TGF-β1 expression increase
상기에서 배양한 세포에 시링가레시놀을 DMSO에 녹여 20, 50, 100 μM 농도로 24시간 처리하였다. 배양 후, 24시간째에 세포 배양액을 채취하였다.The cells cultured in the above were dissolved in DMSO and treated at 20, 50 and 100 μM for 24 hours. After the culture, the cell culture solution was collected at 24 hours.
R&D 시스템(R&D system, 미국)의 ELISA 키트(QuantikineTM high sensitivity ELISA kit)를 사용하여 제조사의 지침에 따라, 채취한 세포 배양액에서 생성된 TGF-β1의 양을 측정하였다. TGF-β1의 양 측정에 필요한 시료는 모두 상기 키트에서 제공하는 것을 사용하였다. 먼저, TGF-β1 항체가 균일하게 도포된 96-웰 마이크로 플레이트에 채취한 세포 배양액을 첨가하여 37℃에서 1시간 동안 항원-항체 반응이 일어나도록 하였다. 웰 내의 세포 배양액을 제거하고 PBS 완충용액으로 3회 세척하였다. 각 웰에 발색 효소 호스라디쉬 퍼옥시다제(horseradish peroxidase)가 결합된 2차 항체를 첨가하여 1시간 동안 항원-항체 반응이 일어나도록 하였다. 다음으로, 각 웰에 발색 유발 물질 테트라메틸벤지딘(tetramethylbenzidine)을 넣고 상온에서 15분간 반응시킨 후, 1 N 황산 용액을 첨가하여 반응을 중지시켰다. 분광 광도계로 450 ㎚의 파장에서 흡광도를 측정하였다. 표준 용액을 이용하여 표준 곡선을 작성하고, 측정한 흡광도를 표준 곡선에 대입하여 각 시료가 첨가된 세포 배양액의 TGF-β1 생성량을 계산하였다. 그 결과는 아래 표와 같다.The amount of TGF-β1 produced in the cell culture medium was measured according to the manufacturer's instructions using an ELISA kit (Quantikine ™ high sensitivity ELISA kit) of the R & D system (USA). All of the samples required for measuring the amount of TGF-? 1 were used as those provided in the kit. First, a cell culture solution collected in a 96-well microplate coated with TGF-? 1 antibody uniformly was added to allow an antigen-antibody reaction to take place at 37 ° C for 1 hour. The cell culture medium in the wells was removed and washed three times with PBS buffer solution. A secondary antibody conjugated with a chromogenic enzyme horseradish peroxidase was added to each well to allow an antigen-antibody reaction to take place for 1 hour. Next, the color development inducer tetramethylbenzidine was added to each well, reacted at room temperature for 15 minutes, and 1 N sulfuric acid solution was added to stop the reaction. Absorbance was measured with a spectrophotometer at a wavelength of 450 nm. A standard curve was prepared using the standard solution, and the absorbance measured was substituted into a standard curve to calculate the amount of TGF-β1 produced in the cell culture medium to which each sample was added. The results are shown in the table below.
상기 결과에서 볼 수 있듯이, 시링가레시놀은 농도 의존적으로 섬유아세포의 TGF-β1 생성을 증가시켰다. 이를 토대로 시링가레시놀은 TGF-β1 생성을 증가시켜 피부 재생을 촉진하고, 나아가 피부 노화를 방지하며 주름을 개선할 수 있음을 알 수 있다.As can be seen from the above results, Sirling's recipin increased TGF-β1 production in fibroblasts in a concentration-dependent manner. Based on this, it can be seen that Sirling's recinol increases TGF-β1 production, promotes skin regeneration, and further prevents skin aging and wrinkles.
[실험예 5] 무모 생쥐 피부에서의 주름 생성 억제 및 표피 수분 손실량 억제 효과 평가[Experimental Example 5] Evaluation of suppression of wrinkle formation and inhibition of skin moisture loss in hairless mouse skin
시링가레시놀의 주름 생성 억제 효과 및 표피 수분 손실량 억제를 평가하기 위해 아래와 같은 실험을 수행하였다.The following experiment was carried out to evaluate the effect of inhibiting wrinkle formation and inhibiting the moisture loss of the skin of Sirlinga lycinol.
1. 무모 생쥐의 처리 1. Treatment of hairless mice
체중이 25-39 g 정도 되는 30 주령의 암컷 무모 생쥐(Skh: HR-1)를 Charles River Laboratories(Wilmington, MA, U.S.A.)로부터 구입하여 사용하였다. 실험 쥐들을 일주일 동안 동물 사육실에서 적응시킨 후 정상군, 시료 처치군으로 군 당 5마리씩 나누어 실험 기간 동안 사육하였다. 사육은 12시간 주기로 조명하는 명암 조건, 23.2℃의 온도 및 55.10%의 습도 조건 하에서 먹이와 물은 자유롭게 섭취할 수 있도록 하여 이루어졌다.A 30-week-old female hamster (Skh: HR-1), weighing 25-39 g, was purchased from Charles River Laboratories (Wilmington, MA, U.S.A.). Experimental rats were adapted for one week in an animal breeding room, and were divided into 5 normal and 5 experimental groups. Breeding was carried out in such a way that food and water could be freely consumed under light and dark conditions illuminating at 12-hour intervals, temperature of 23.2 ° C and humidity of 55.10%.
2. 시링가레시놀의 피부 도포 또는 경구 투여에 의한 피부 주름 생성 억제 효과 평가2. Evaluation of the effect of inhibiting skin wrinkle formation by the skin application or oral administration of Siringagrelinol
시료 처치군에는 1% 농도로 용매(1,3-부틸렌 글리콜:에탄올 = 7:3)에 녹인 시링가레시놀을 패취의 형태로 2일간 2회 처치하거나, 200mg/kg 농도의 시링가레시놀을 4주간 경구 투여 하였다. 대조군에는 시링가레시놀 대신 동일한 양의 용매를 같은 방법으로 처치하였다. 시링가레시놀을 도포한 군 및 그 대조군, 시링가레시놀을 경구 투여한 군 및 그 대조군에 대해 각각 180 mJ/cm2의 UVB를 조사하였다. 자외선을 조사하기 전 주름 상태와 자외선 조사 후의 동일한 부위에 대한 주름을 레플리카(replica)로 떠서 비시오메타 시스템(Visiometer system; C+K사)으로 피부 주름을 측정하였다. 피부 주름 변화량을 아래 수학식에 따라 계산하였으며, 그 결과를 도 7에 나타내었다.In the sample treatment group, siring ginsenoside dissolved in a solvent (1,3-butylene glycol: ethanol = 7: 3) at a concentration of 1% was treated twice in two days in the form of a patch, or 200 mg / NOL was orally administered for 4 weeks. In the control group, the same amount of solvent was treated in the same manner in place of Sirling's resinol. UVB of 180 mJ / cm 2 was irradiated to the group to which Sirling regimen was applied and the control group, the group to which Sirling regimen was orally administered and the control group respectively. The wrinkles of the wrinkles and the wrinkles of the same area after irradiation with ultraviolet rays were removed with a replica before UV irradiation, and skin wrinkles were measured with a Visiometer system (C + K). The amount of skin wrinkle change was calculated according to the following equation, and the result is shown in FIG.
[수학식][Mathematical Expression]
변화량(%)={(Tdi-Tdo)/(Tdo)}x100Change amount (%) = {(T di- T do ) / (T do )} x 100
Tdi: 실험 종료 후 피부 주름 측정 부위 값T di : value of skin wrinkle measurement site after end of experiment
Tdo: 자외선 조사 전 피부 주름 측정 부위 값 T do : Wrinkle measurement site value before ultraviolet irradiation
도 7에서 볼 수 있듯이, 도포 및 경구 투여 대조군의 피부 주름은 각각 230±35%, 224±45%로 증가한 반면, 시링가레시놀을 도포한 군 및 경구 투여한 군의 피부 주름은 각각 121±35%, 123±25%로 매우 근소한 증가만을 나타내었다. 이를 통해 시링가레시놀은 우수한 주름 방지 억제 효과를 가짐을 확인할 수 있다.As can be seen from FIG. 7, the skin wrinkles of the treated and oral control groups were increased to 230 ± 35% and 224 ± 45%, respectively, whereas the skin wrinkles of the group treated with Siring regresin and oral group were 121 ± 35% and 123 ± 25%, respectively. As a result, it can be confirmed that Siringagresin has excellent anti-wrinkle effect.
3. 표피 수분 손실량(TEWL, transepidermal water loss) 측정3. Measurement of transepidermal water loss (TEWL)
실험 시작 3주 후에 Delfin vapometer wireless(Technologies ltd. SWL 4102)를 이용하여 각 군의 무모 쥐의 등 부위 피부에서 경표피 수분 손실량(Trans-Epidermal Water Loss, TEWL)을 측정하고, 그 결과를 도 8에 나타내었다. 측정 당시 환경 조건은 상대 습도 60±5%, 온도 25.5±0.5℃이었다.Three weeks after the start of the experiment, Trans-Epidermal Water Loss (TEWL) was measured in the dorsal skin of each group using Delfin vapometer wireless (Technologies ltd. SWL 4102) Respectively. The environmental conditions at the time of measurement were relative humidity 60 ± 5% and temperature 25.5 ± 0.5 ℃.
경표피 수분 손실량은 피부로부터 발산되는 수분량으로서 이 수치가 높을 수록 피부의 보습 기능이 떨어져 있으며, 피부 고유의 장벽 기능이 손상되었음을 의미한다. 따라서 경표피 수분 손실량은 피부 장벽 기능, 피부 장벽 손상 후의 회복 정도, 자외선과 같은 자극에 대한 피부 보호 효과 등을 판정함에 있어 지표로 사용될 수 있다. The amount of water-loss of the light skin is the amount of moisture emitted from the skin. The higher the value, the lower the moisturizing function of the skin and the impairment of the inherent barrier function of the skin. Therefore, the amount of water-loss of the epidermis can be used as an index in determining the skin barrier function, the degree of recovery after skin barrier damage, and the skin protection effect against stimuli such as ultraviolet rays.
도 8에서 볼 수 있듯이, UV를 조사하는 경우 피부 장벽이 손상되어 피부 보습 기능이 감소하며, 시링가레시놀을 경구 섭취 또는 도포하면 자외선에 의해 유발되는 경표피 수분 손실량이 감소된다. 이를 통해, 시링가레시놀은 자외선에 의한 피부 수분 손실을 막아 우수한 피부 장벽 기능 회복, 외부 자극에 대한 피부 보호 및 피부 보습 효과를 가짐을 알 수 있다.As can be seen from FIG. 8, when UV irradiation is applied, the skin barrier is damaged and the skin moisturizing function is decreased. When the oral ingestion or application of Sirling's Recinol is performed, the amount of moisture loss caused by ultraviolet rays is decreased. Through this, it can be seen that Sirling Gelsinol has excellent skin barrier function recovery, skin protection against external stimulation and skin moisturizing effect by preventing loss of skin moisture due to ultraviolet rays.
본 발명의 일측면에 따른 조성물의 제형예를 아래에서 설명하나, 다른 여러 가지 제형으로도 응용 가능하며, 이는 본 발명을 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Formulation examples of compositions according to one aspect of the present invention are described below, but may be applied to various other formulations, which are not intended to be limiting but merely illustrative of the invention.
[제형예 1] 로션[Formulation Example 1] Lotion
아래 표에 기재된 조성으로 통상의 방법에 따라 로션을 제조한다.The lotion is prepared according to a conventional method with the composition shown in the following table.
[제형예 2] 크림[Formulation Example 2] Cream
아래 표에 기재된 조성으로 통상의 방법에 따라 크림을 제조한다.Creams are prepared according to a conventional method with the composition shown in the following table.
[제형예 3] 팩[Formulation Example 3] Pack
아래 표에 기재된 조성으로 통상의 방법에 따라 팩을 제조한다.A pack is prepared according to a conventional method with the composition shown in the following table.
[제형예 4] 연질 캅셀제[Formulation Example 4] Soft capsule
시링가레시놀 100 mg, 대두추출물 50 mg, 대두유 180 mg, 홍삼추출물 50 mg, 팜유 2 mg, 팜경화유 8 mg, 황납 4 mg 및 레시틴 6 mg을 혼합하고, 통상의 방법에 따라 연질 캅셀을 제조한다.A soft capsule was prepared according to a conventional method by mixing 100 mg of siringagrecinol, 50 mg of soybean extract, 180 mg of soybean oil, 50 mg of red ginseng extract, 2 mg of palm oil, 8 mg of palm kernel oil, 4 mg of yellow pearls and 6 mg of lecithin. do.
[제형예 5] 정제[Formulation Example 5] Tablets
시링가레시놀 100 mg, 대두 추출물 50 mg, 포도당 100 mg, 홍삼 추출물 50 mg, 전분 96 mg 및 마그네슘 스테아레이트 4 mg을 혼합하고 30% 에탄올을 40 mg 첨가하여 과립을 형성한 후 건조하고 정제로 타정한다.100 mg of siringagrecinol, 50 mg of soybean extract, 100 mg of glucose, 50 mg of red ginseng extract, 96 mg of starch and 4 mg of magnesium stearate were mixed and 40 mg of 30% ethanol was added to form granules, followed by drying and refining It is punishable.
[제형예 6] 건강 식품[Formulation Example 6] Health food
시링가레시놀................... 1000 ㎎ Siringa glycine ................... 1000 mg
비타민 혼합물 Vitamin mixture
비타민 A 아세테이트...............70 ㎍ Vitamin A Acetate ............... 70 ㎍
비타민 E ....................... 1.0 ㎎ Vitamin E ....................... 1.0 mg
비타민 B1...................... 0.13 ㎎ Vitamin B1 ...................... 0.13 mg
비타민 B2 ...................... 0.15 ㎎ Vitamin B2 ...................... 0.15 mg
비타민 B6........................ 0.5 ㎎ Vitamin B6 ........................ 0.5 mg
비타민 B12....................... 0.2 ㎍ Vitamin B12 ....................... 0.2 g
비타민 C.......................... 10 ㎎ Vitamin C .......................... 10 mg
비오틴............................. 10 ㎍ Biotin ............................. 10 μg
니코틴산아미드.................... 1.7 ㎎ Nicotinic acid amide ... 1.7 mg
엽산............................... 50 ㎍ Folic acid ............................... 50 ㎍
판토텐산 칼슘..................... 0.5 ㎎ Calcium pantothenate ..................... 0.5 mg
무기질 혼합물 Mineral mixture
황산제1철........................ 1.75 ㎎ Ferrous sulfate ........................ 1.75 mg
산화아연.......................... 0.82 ㎎ Zinc oxide .......................... 0.82 mg
탄산마그네슘...................... 25.3 ㎎ Magnesium carbonate ...................... 25.3 mg
제1인산칼륨......................... 15 ㎎Potassium Phosphate ......................... 15 mg
제2인산칼슘......................... 55 ㎎ Secondary Calcium Phosphate ..................... 55 mg
구연산칼륨.......................... 90 ㎎ Potassium citrate .......................... 90 mg
탄산칼슘........................... 100 ㎎ Calcium carbonate ........................... 100 mg
염화마그네슘...................... 24.8 ㎎ Magnesium chloride ...................... 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강 식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하다.Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with the ingredient suitable for health food as a preferred embodiment, the compounding ratio thereof may be arbitrarily modified.
[제형예 7] 건강 음료[Formulation Example 7] Health drinks
시링가레시놀.......................... 1000 ㎎ Siringa glycine .......................... 1000 mg
구연산................................ 1000 ㎎ Citric acid ................................ 1000 mg
올리고당................................ 100 g Oligosaccharides ................................ 100 g
타우린.................................... 1 g Taurine .................................... 1 g
정제수............ ..................... 잔량 Purified water ............ ..................... Remaining amount
통상의 건강 음료 제조 방법에 따라 상기의 성분을 혼합한 다음, 약 1시간 동안 약 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균한다.The above components are mixed according to a conventional health drink manufacturing method, and the mixture is stirred and heated at about 85 캜 for about 1 hour, and then the prepared solution is sterilized by filtration.
Claims (6)
상기 조성물은 피부 보습용, 및 피부장벽강화용으로 이루어진 군으로부터 선택된 1 이상의 용도를 가지는 것인, 화장료 또는 건강 식품 조성물.A cosmetic or health food composition comprising syringaresinol as an active ingredient,
Wherein the composition has at least one use selected from the group consisting of skin moisturizing and skin barrier strengthening.
시링가레시놀은 아마씨, 황백, 오가피, 참깨 및 인삼 열매 중 선택된 하나 이상의 추출물로부터 분리되는 것인, 화장료 또는 건강 식품 조성물.The method according to claim 1,
Wherein the siring ginsenoside is separated from one or more extracts selected from flaxseed, yellow-white, ocher, sesame and ginseng.
조성물은 조성물 전체 중량을 기초로 1 중량% 내지 80 중량%의 시링가레시놀을 포함하는, 화장료 또는 건강 식품 조성물.The method according to claim 1,
Wherein the composition comprises from 1% to 80% by weight, based on the total weight of the composition, of a singling glycerin.
조성물은 SIRT 1(Sirtuin 1)의 발현을 촉진하는, 화장료 또는 건강 식품 조성물.The method according to claim 1,
Wherein the composition promotes the expression of SIRT 1 (Sirtuin 1).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180066106A KR101972073B1 (en) | 2018-06-08 | 2018-06-08 | Composition for inhibition of aging comprising syringaresinol |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180066106A KR101972073B1 (en) | 2018-06-08 | 2018-06-08 | Composition for inhibition of aging comprising syringaresinol |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020110112764A Division KR101876472B1 (en) | 2011-10-27 | 2011-11-01 | Composition for inhibition of aging comprising syringaresinol |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20180068914A KR20180068914A (en) | 2018-06-22 |
KR101972073B1 true KR101972073B1 (en) | 2019-04-24 |
Family
ID=62768657
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020180066106A KR101972073B1 (en) | 2018-06-08 | 2018-06-08 | Composition for inhibition of aging comprising syringaresinol |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101972073B1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115487113B (en) * | 2022-09-26 | 2024-01-16 | 海南大学 | Emulsion containing clove fruit extract and preparation method and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005048970A1 (en) * | 2003-11-20 | 2005-06-02 | Basf Aktiengesellschaft | Use of lignans in cosmetic or dermatological preparations |
JP2009067718A (en) * | 2007-09-12 | 2009-04-02 | Lb Maple Treat Inc | Skin preparation for external use containing phenolic compound in sap of plant of aceraceae |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100670237B1 (en) | 2003-11-13 | 2007-01-17 | 주식회사 사임당화장품 | Cosmetic composition containing Safflower Seed Extract and extraction method of cosmetic effective composition from Safflower Seed |
-
2018
- 2018-06-08 KR KR1020180066106A patent/KR101972073B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005048970A1 (en) * | 2003-11-20 | 2005-06-02 | Basf Aktiengesellschaft | Use of lignans in cosmetic or dermatological preparations |
JP2009067718A (en) * | 2007-09-12 | 2009-04-02 | Lb Maple Treat Inc | Skin preparation for external use containing phenolic compound in sap of plant of aceraceae |
Also Published As
Publication number | Publication date |
---|---|
KR20180068914A (en) | 2018-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101517950B1 (en) | Cosmetic composition with mucus from sturgeon | |
KR100825450B1 (en) | Skin anti-wrinkle cosmetics composition containing Forsythiae Fruit extract | |
KR101824770B1 (en) | Anti-wrinkle cosmetic composition comprising essentially Polygonum multiflorum adventitious extract | |
KR20130135165A (en) | Agent for improving skin and hair containing extract of leontopodium alpinum treated enzyme | |
KR101436199B1 (en) | Composition for Improving Skin Conditions Comprising Hordenine | |
KR101026879B1 (en) | Producing method of cosmetic composition for improving skin wrinkle | |
KR101135444B1 (en) | Cosmetic composition for improvement of the skin wrinkles containing Palmitoyl Oligo peptide and Eucommia ulmoides extract | |
KR20150059551A (en) | Composition for improving skin conditions comprising panax ginseng sprout extract or fraction thereof and method for improving skin conditions using the same | |
KR100710657B1 (en) | Whitening cosmetic composition containing dihydroquercetin | |
KR101972073B1 (en) | Composition for inhibition of aging comprising syringaresinol | |
KR20110023435A (en) | Composition containing glycoproteins extract from plant | |
KR101591499B1 (en) | Composition for skin whitening comprising amaranthus spp. l. extract or fraction thereof | |
CN111135124B (en) | Skin external composition containing mixture of sucrose, indole-3-acetic acid and fructus Rosae Davuricae extract | |
EP2772255B1 (en) | Composition comprising syringaresinol for improving the skin | |
KR20140097865A (en) | Cosmetic composition comprising Laver extract for anti-inflammation | |
KR102337308B1 (en) | Composition for preventing or improving skin aging containing (-)-eudesmin | |
KR101876472B1 (en) | Composition for inhibition of aging comprising syringaresinol | |
KR20090097550A (en) | Cosmetic composition containing schizandrin and extracts | |
KR20090036904A (en) | Cosmetic compositions comprising prunella vulgaris extract and adenosine | |
KR20180072379A (en) | Composition for improving skin condition comprising extract of lily bulblet | |
KR20090078084A (en) | The cosmetic composition for improvement of the skin wrinkles containing adenosine and eucommia ulmoides extract | |
KR20090050856A (en) | Skin whitening cosmetic composition containing fraction extract of cimicifuga heracleifolia extracts, manufacturing method thereof | |
KR102215164B1 (en) | Composition for preventing or improving skin aging containing acetic acid 16-hydroxy-octadeca-9,17-diene-12,14-diynyl ester | |
KR101176524B1 (en) | Cosmetic Composition for Anti-Aging Comprising Flavonoid as Active Ingredients | |
KR102601551B1 (en) | Composition for skin improvement containing liriopesides B |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) | ||
GRNT | Written decision to grant |